Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

• Verfasst von: Merz, Patrick [VerfasserIn]
• Verfasst von: Ballikaya, Seda [VerfasserIn]
• Verfasst von: Auffarth, Gerd U. [VerfasserIn]
• Verfasst von: Schmack, Ingo [VerfasserIn]
• Titel: Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
• Verf.angabe: Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack
• E-Jahr: 2018
• Jahr: 11 December 2018
• Umfang: 8 S.
• Fussnoten: Gesehen am 21.12.2018
• Titel Quelle: Enthalten in: BMC ophthalmology
• Ort Quelle: London : BioMed Central, 2001
• Jahr Quelle: 2018
• Band/Heft Quelle: 18(2018), Artikel-ID 316
• ISSN Quelle: 1471-2415
• DOI: doi:10.1186/s12886-018-0978-9
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 158583341X
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium.